We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

75 hedge funds and large institutions have $55.1M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 30 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $35.5M → $55.1M (+$19.7M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less funds holding

Funds holding: 83 → 75 (-8)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

50% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 30

Holders
75
Holders Change
-8
Holders Change %
-9.64%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
15
Reduced
30
Closed
23
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
TC
Trium Capital
United Kingdom
+$1.45M
2
ACM
ADAR1 Capital Management
Texas
+$1.21M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$535K
4
Citadel Advisors
Citadel Advisors
Florida
+$401K
5
N
Natixis
France
+$269K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.05M
2
Millennium Management
Millennium Management
New York
-$1.77M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.15M
4
N
Nuveen
North Carolina
-$787K
5
Two Sigma Investments
Two Sigma Investments
New York
-$686K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Column Group
California
$28.8M – – –
BlackRock
2
BlackRock
New York
$4.78M -$258K -173,955 -5%
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.7M -$662K -446,182 -16%
SG
4
StepStone Group
California
$2.5M – – –
EC
5
Euclidean Capital
New York
$1.58M – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.56M +$92.3K +62,226 +7%
TC
7
Trium Capital
United Kingdom
$1.55M +$1.45M +977,965 New
State Street
8
State Street
Massachusetts
$1.31M +$1.06K +712 +0.1%
ACM
9
ADAR1 Capital Management
Texas
$1.3M +$1.21M +816,581 New
Renaissance Technologies
10
Renaissance Technologies
New York
$972K -$216K -145,592 -19%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$804K -$120K -81,000 -14%
Northern Trust
12
Northern Trust
Illinois
$593K +$52.6K +35,451 +11%
Balyasny Asset Management
13
Balyasny Asset Management
Illinois
$573K +$535K +360,599 New
Citadel Advisors
14
Citadel Advisors
Florida
$544K +$401K +270,021 +374%
Charles Schwab
15
Charles Schwab
California
$453K +$8.82K +5,945 +2%
Goldman Sachs
16
Goldman Sachs
New York
$333K +$146K +98,616 +89%
ETC
17
Exchange Traded Concepts
Oklahoma
$296K +$117K +79,213 +74%
N
18
Natixis
France
$288K +$269K +181,366 New
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
$273K -$73.1K -49,259 -22%
Morgan Stanley
20
Morgan Stanley
New York
$247K -$245K -165,460 -52%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$246K – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$212K -$8.7K -5,865 -4%
Citigroup
23
Citigroup
New York
$171K +$148K +100,093 +1,355%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$156K +$145K +98,037 New
N
25
Nuveen
North Carolina
$150K -$787K -530,354 -85%
1
2 3 4

NGM Hedge Fund Activity: Q1 2024 in Review

75 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2024, worth a combined $55.1M — up 56% from $35.5M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of NGM and 15 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 15 added.

The largest buyer was Trium Capital, opening a new position worth an estimated $1.45M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.05M sold.

  • 75 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2024, down from 83 in Q4 2023.
  • Funds reported $55.1M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2024, up 56% quarter-over-quarter.
  • 15 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2024 and 23 closed out, a net change of -8 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Trium Capital, an estimated $1.45M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2024 was EcoR1 Capital, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2024.